Discovery of mutant IDH2 inhibitors for the treatment of cancer

被引：0

作者：

Travins, Jeremy M. ^{[1
]}

Popovici-Muller, Janeta ^{[1
]}

DeLaBarre, Byron ^{[2
]}

Gross, Stefan ^{[2
]}

Yang, Hua ^{[4
]}

Wang, Fang ^{[3
]}

Yen, Katherine E. ^{[3
]}

Salituro, Francesco G. ^{[1
]}

Saunders, Jeffrey O. ^{[1
]}

Dang, Lenny ^{[2
]}

Biller, Scott A. ^{[1
]}

机构：

[1] Agios Pharmaceut, Dept Chem, Cambridge, MA 02139 USA

[2] Agios Pharmaceut, Dept Biochem, Cambridge, MA 02139 USA

[3] Agios Pharmaceut, Dept Biol, Cambridge, MA 02139 USA

[4] Agios Pharmaceut, Dept Drug Metab & Pharmacokinet, Cambridge, MA 02139 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2013年 / 246卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

200-MEDI

引用

页数：1

共 50 条

[1] Inhibitors of mutant IDH1 and IDH2
Pamela Feliciano
Nature Genetics, 2013, 45 (5) : 477 - 477
[2] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, Samah
Lap, Coen J.
Haroun, Faysal
Tabbara, Imad
ANNALS OF HEMATOLOGY, 2017, 96 (12) : 1983 - 1991
[3] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Samah Nassereddine
Coen J. Lap
Faysal Haroun
Imad Tabbara
Annals of Hematology, 2017, 96 : 1983 - 1991
[4] Inhibitors of Mutant IDH for the Treatment of Cancer
Abdel-Magid, Ahmed F.
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (11): : 1184 - 1185
[5] Induction of sarcomas by mutant IDH2
Lu, Chao
Venneti, Sriram
Akalin, Altuna
Fang, Fang
Ward, Patrick S.
DeMatteo, Raymond G.
Intlekofer, Andrew M.
Chen, Chong
Ye, Jiangbin
Hameed, Meera
Nafa, Khedoudja
Agaram, Narasimhan P.
Cross, Justin R.
Khanin, Raya
Mason, Christopher E.
Healey, John H.
Lowe, Scott W.
Schwartz, Gary K.
Melnick, Ari
Thompson, Craig B.
GENES & DEVELOPMENT, 2013, 27 (18) : 1986 - 1998
[6] Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, Alexandra
Seltzer, Meghan J.
Riggins, Gregory J.
CURRENT OPINION IN ONCOLOGY, 2012, 24 (01) : 83 - 89
[7] Hitting the target in IDH2 mutant AML
Wouters, Bas J.
BLOOD, 2017, 130 (06) : 693 - 694
[8] The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Abou Dalle, Iman
DiNardo, Courtney D.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (07) : 163 - 173
[9] Structural Biology of Mutant IDH2 Inhibition
DeLaBarre, B.
Wang, F.
Travins, J.
Gross, S.
Artin, E.
Dang, L.
Biller, S.
Yen, K.
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 : C799 - C799
[10] IDH2 Inhibitors Gain a Wildcard Status in the Cancer Therapeutics Competition
Piva, Roberto
Gharari, Nariman
Labrador, Maria
Mader, Sylvie
CANCERS, 2024, 16 (19)

← 1 2 3 4 5 →